Royal Brisbane & Women's Hospital Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2018
NCT03508453
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Royal Brisbane & Women's Hospital

Active Ingredients

Drugs in Phase 2 Trials (3)

[212pb]pb-advc001 (1 trial)

ic14 (1 trial)

trimetazidine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyotrophic Lateral Sclerosis (Phase 2)

Motor Neuron Disease (Phase 2)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3